Zyvox Dosage
Generic name: linezolid
Dosage form: injection, tablets, oral suspension
This dosage information does not include all the information needed to use Zyvox safely and effectively. See full prescribing information for Zyvox.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
The recommended dosage for ZYVOX formulations for the treatment of infections is described in Table 14.
Infection* |
Dosage and Route of Administration | Recommended Duration of Treatment (consecutive days) | |
|---|---|---|---|
| Pediatric Patients† (Birth through 11 Years of Age) | Adults and Adolescents (12 Years and Older) | ||
|
|||
| Complicated skin and skin structure infections | 10 mg/kg IV or oral‡ q8h | 600 mg IV or oral‡ q12h | 10 to 14 |
| Community-acquired pneumonia, including concurrent bacteremia | |||
| Nosocomial pneumonia | |||
| Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia | 10 mg/kg IV or oral‡ q8h | 600 mg IV or oral‡ q12h | 14 to 28 |
| Uncomplicated skin and skin structure infections | <5 yrs: 10 mg/kg oral‡ q8h 5–11 yrs: 10 mg/kg oral‡ q12h |
Adults: 400 mg oral‡ q12h Adolescents: 600 mg oral‡ q12h |
10 to 14 |
Adult patients with infection due to MRSA should be treated with ZYVOX 600 mg q12h.
In limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to Gram-positive pathogens with MICs of 4 µg/mL treated with ZYVOX had clinical cures. However, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (AUC) compared with adults. In pediatric patients with a sub-optimal clinical response, particularly those with pathogens with MIC of 4 µg/mL, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response (see CLINICAL PHARMACOLOGY, Special Populations, Pediatric and PRECAUTIONS, Pediatric Use).
In controlled clinical trials, the protocol-defined duration of treatment for all infections ranged from 7 to 28 days. Total treatment duration was determined by the treating physician based on site and severity of the infection, and on the patient's clinical response.
No dose adjustment is necessary when switching from intravenous to oral administration. Patients whose therapy is started with ZYVOX I.V. Injection may be switched to either ZYVOX Tablets or Oral Suspension at the discretion of the physician, when clinically indicated.
Intravenous Administration
ZYVOX I.V. Injection is supplied in single-use, ready-to-use infusion bags (see HOW SUPPLIED for container sizes). Parenteral drug products should be inspected visually for particulate matter prior to administration. Check for minute leaks by firmly squeezing the bag. If leaks are detected, discard the solution, as sterility may be impaired.
ZYVOX I.V. Injection should be administered by intravenous infusion over a period of 30 to 120 minutes. Do not use this intravenous infusion bag in series connections. Additives should not be introduced into this solution. If ZYVOX I.V. Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each product. In particular, physical incompatibilities resulted when ZYVOX I.V. Injection was combined with the following drugs during simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isothionate, erythromycin lactobionate, phenytoin sodium, and trimethoprim-sulfamethoxazole. Additionally, chemical incompatibility resulted when ZYVOX I.V. Injection was combined with ceftriaxone sodium.
If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of ZYVOX I.V. Injection with an infusion solution compatible with ZYVOX I.V. Injection and with any other drug(s) administered via this common line (see Compatible Intravenous Solutions).
Compatible Intravenous Solutions
5% Dextrose Injection, USP
0.9% Sodium Chloride Injection, USP
Lactated Ringer's Injection, USP
Keep the infusion bags in the overwrap until ready to use. Store at room temperature. Protect from freezing. ZYVOX I.V. Injection may exhibit a yellow color that can intensify over time without adversely affecting potency.
Constitution of Oral Suspension
ZYVOX for Oral Suspension is supplied as a powder/granule for constitution. Gently tap bottle to loosen powder. Add a total of 123 mL distilled water in two portions. After adding the first half, shake vigorously to wet all of the powder. Then add the second half of the water and shake vigorously to obtain a uniform suspension. After constitution, each 5 mL of the suspension contains 100 mg of linezolid. Before using, gently mix by inverting the bottle 3 to 5 times. DO NOT SHAKE. Store constituted suspension at room temperature. Use within 21 days after constitution.
